medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2012, Number 3

<< Back Next >>

Biotecnol Apl 2012; 29 (3)

Interferon alpha-2b and ribavirin as combined therapy for chronic hepatitis C in Cuba: National Program

Nodarse-Cuní H, Arús-Soler E, Rivera-Reimón LL, Pérez-Lorenzo M, Samada-Suárez M, García-Ferrera WO, Sánchez-Rodríguez YA, Pupo-Oliveros D, Obregón-Moreno A, Umpierre-García I, Martínez-Martínez O, Moret-Pérez A, González-González Y, Bermúdez-Hernández Y, García-Iglesias E, Lazo-Diago OC, López-Saura P

Language: English
References: 40
Page: 184-188
PDF size: 176.77 Kb.


ABSTRACT

The treatment of chronic hepatitis C with interferon alpha (IFN-α) is widely used. However, the relapse rate is high, and sustained response is only in 10-20%. A combined treatment based on the synergic antiviral effects described for IFN-α and ribavirin was used as a National Program in Cuba. The study enrolled 357 patients treated during 48 weeks with an injection of IFN-α, 3 times weekly, combined with oral ribavirin in daily doses, the doses adjusted to body weight. Sustained virological response was the efficacy end point, supported by biochemical and histological changes. Normalization in transaminase levels occurs in 60.5% of patients after the first 4 weeks, 71.4% at 26 weeks and 60.2% at the end of treatment. In similar moments, the viral load was undetectable in 42.9%, 42.6% and 37.0% respectively. The implementation of this National Program led to 49.0% and 29.7% of biochemical and virological sustained response respectively. A histological improvement was observed in 53.5% of evaluated patients. The treatment was well tolerated and almost all adverse reactions were attributable to IFN-α. The main adverse reports were: anemia, leucopenia, asthenia, fever, headache, arthralgias, anorexia and myalgia. Anti-interferon antibodies were developed in 38 patients, in 3 of them as neutralizing of antiviral activity. These results confirm the efficacy and security profile of both drugs as combined therapy for the chronic hepatitis C and represent the first clinical data generated from its extensive use in the Cuban general population. The virological response was in agreement with international reports for populations with similar characteristics.


REFERENCES

  1. Nash KL, Bentley I, Hirschfield GM. Managing hepatitis C virus infection. BMJ. 2009;338:b2366.

  2. Jacobson IM, Davis GL, El-Serag H, Negro F, Trepo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8(11):924-33.

  3. Pears E. Hepatitis C virus infection: risk factors, diagnosis and management. Nurs Stand. 2010;25(15-17):49-56.

  4. Ferrant O, Bazin A, Girard A, Le Coutour X, Leporrier M, Papin F. Post-transfusion hepatitis C. From screening to compensation. Transfus Clin Biol. 2010;17(2):47-53.

  5. Albeldawi M, Ruiz-Rodriguez E, Carey WD. Hepatitis C virus: Prevention, screening, and interpretation of assays. Cleve Clin J Med. 2010;77(9):616-26.

  6. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36(2):91-133.

  7. Fallahian F, Najafi A. Epidemiology of hepatitis C in the Middle East. Saudi J Kidney Dis Transpl. 2011;22(1):1-9.

  8. Padrón G, Arús E, Roca J, Viña A, Lemus G, Bacallao J. The Hepatitis C in Cuba: prevalence, antibody pattern, genotype and risk factor [abstract]. Hepatology. 1994;19(4):I141.

  9. Merion RM. Current status and future of liver transplantation. Semin Liver Dis. 2010;30(4):411-21.

  10. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321(22):1506-10.

  11. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Jr., Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321(22):1501-6.

  12. Marcellin P, Bourliere M, Pawlotsky JM, Ouzan D. HCV non-responder patients: definition of non-response and treatment strategy. Gastroenterol Clin Biol. 2007;31(8-9 Pt 3):4S13-9.

  13. Poordad FF, Flamm SL. Virological relapse in chronic hepatitis C. Antivir Ther. 2009;14(3):303-13.

  14. Bodenheimer HC, Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26(2):473-7.

  15. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992;16(3):649-54.

  16. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology. 2011;53(1):32-41.

  17. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-92.

  18. Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009;43(7):661-71.

  19. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19(3):1-46.

  20. Arús E, Infante M, Padrón G, Morales MG, Grá B, Soto G, et al. Interferón alfa-2b recombinante en hepatitis C crónica: Resultados del tratamiento y determinación de anticuerpos anti-interferón. Biotecnol Apl. 1997;14(4):242-7.

  21. Arús E, Rivera L, Fernández A, Infante M, Díaz RJ, Soto G, et al. Tratamiento de la hepatitis crónica C con interferón alfa2b recombinante. Ensayo clínico controlado aleatorizado. Rev Cubana Med. 2000;39(1):12-20.

  22. Arús E, Rivera L, Infante M, Pérez M, Soto G, Grá B, et al. Tratamiento de la hepatitis viral aguda C con interferón alfa 2b recombinante. Ensayo clínico. Rev Cubana Med. 2000;39(1):21-9.

  23. Galbán E, Vega H. Interferón alfa-2b en hepatitis crónica C. Combinación con Ribavirina. GEN. 2000;54(3):169-86.

  24. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431-5.

  25. González-Cabañas R, Ferrero-Bibilonia J, Morales-Menéndez MG, Aguilera-Rodríguez A, López-Saura P. Inmunogenicidad del interferón alfa-2b recombinante (Heberon alfa R®). Detección de anticuerpos mediante un ensayo inmunoenzimático y neutralización de actividad antiviral. Biotecnol Apl. 1998;15:71-6.

  26. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2009. La Habana: Ministerio de Salud Pública de Cuba. Available from: http://files.sld.cu/dne/files/2010/04/anuario-2009e3.pdf.

  27. Alves AV, Azevedo APC, Perin C, Ramos GZ, Brandão ABM, Mattos AA, et al. Tratamento de pacientes com hepatite crônica pelo vírus C com interferon-α e ribavirina: a experiência da Secretaria de Saúde do Rio Grande do Sul. Arq Gastroenterol. 2003;40(4):227-32.

  28. Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2005;165(19):2206-12.

  29. Seeff LB, Ghany MG. Management of untreated and nonresponder patients with chronic hepatitis C. Semin Liver Dis. 2010;30(4):348-60.

  30. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011; 52(7):889-900.

  31. Rodriguez-Torres M. Latinos and chronic hepatitis C: a singular population. Clin Gastroenterol Hepatol. 2008;6(5):484-90.

  32. Shiffman ML. Treatment of hepatitis C in 2011: what can we expect? Curr Gastroenterol Rep. 2010;12(1):70-5.

  33. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350-9.

  34. Witthoft T, Moller B, Wiedmann KH, Mauss S, Link R, Lohmeyer J, et al. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. J Viral Hepat. 2007;14(11):788-96.

  35. Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, Francois C. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther. 2010;15(5):687-95.

  36. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol. 2010;24(2):183-92.

  37. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, et al. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver. 1993;13(3):146-50.

  38. Jorns C, Holzinger D, Thimme R, Spangenberg HC, Weidmann M, Rasenack J, et al. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha. J Med Virol. 2006;78(1):74-82.

  39. Spiegel RJ, Jacobs SL, Treuhaft MW. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. J Interferon Res. 1989;9 Suppl 1:S17-24.

  40. Ryff JC. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res. 1997;17 Suppl 1:S29-33.




2020     |     www.medigraphic.com